Thrombin

Thrombin inhibitors block the serine protease that converts fibrinogen into fibrin at the end of coagulation. Thrombin also activates platelets and other cells through protease-activated receptors (PARs). The receptor cloned in 1991 showed that thrombin cleaves the receptor N-terminus and unmasks a tethered ligand. Direct inhibitors bind the active site and are used in coagulation, platelet and vascular research. Dabigatran came from a structure-based design program reported in 2002, and dabigatran etexilate is its orally available prodrug. Argatroban, bivalirudin, inogatran and ximelagatran are further direct thrombin inhibitors. Atopaxar hydrobromide acts on the receptor side as a PAR-1 antagonist, whereas RWJ-445167 inhibits both thrombin and factor Xa.

2 Items

  • TRAP-14
    Cat. No.
    A77888

    TRAP-14

    Synonyms: SFLLRNPNDKYEPF

    TRAP-14 (SFLLRNPNDKYEPF) is a synthetic peptide that acts as an agonist for the thrombin receptor. This compound is utilized in research to study thrombin signaling pathways and their implications in various physiological and pathological processes. Its ability to activate the thrombin receptor makes it valuable for investigating thrombosis, inflammation, and cardiovascular diseases.

    1 mg
    $55.00
    5 mg
    $230.00
    All 3 sizes
  • Thrombin receptor peptide ligand
    Cat. No.
    A77905

    Thrombin receptor peptide ligand

    Thrombin receptor peptide ligand is a selective antagonist of the thrombin receptor, inhibiting its activation and downstream signaling. This compound exhibits antithrombotic properties, making it suitable for research focused on thrombotic disorders and cardiovascular diseases. Its ability to modulate thrombin activity positions it as a valuable tool for studying platelet aggregation and related pathways.

    Out of stock

    All 3 sizes

2 Items

Added to your cart

View Cart Checkout

    Loading...